Form 4: Pulse Biosciences CCO Exercises, Sells Shares

Pulse Biosciences' Chief Commercial Officer, Kevin Patrick Danahy, exercised stock options and subsequently sold an equal number of shares under a pre-arranged 10b5-1 trading plan.

Summary

• Kevin Patrick Danahy, Chief Commercial Officer of Pulse Biosciences, Inc. (PLSE), engaged in transactions on February 18, 2026.
• Exercised options to acquire 5,000 shares of common stock at an exercise price of $1.53 per share.
• Sold 5,000 shares of common stock at a weighted average price of $23.64 per share, with individual sale prices ranging from $22.40 to $24.40.
• These transactions were conducted under a Rule 10b5-1 trading plan adopted on May 14, 2025.
• Following these transactions, Danahy beneficially owns 43,298 shares of common stock directly and 300,000 derivative securities (stock options).

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. While an insider sale occurred, it was pre-planned and represents a realization of value from previously granted options, which is a normal part of executive compensation.

Positives

• The Chief Commercial Officer realized a significant profit by exercising options at $1.53 and selling shares at a weighted average price of $23.64.
• Transactions were executed under a pre-established Rule 10b5-1 trading plan, indicating planned rather than reactive selling.

Negatives

• An insider sold 5,000 shares of common stock, which could be interpreted as a reduction in direct equity exposure.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider transactions, particularly those executed under Rule 10b5-1 plans, are a common practice for executives managing their personal portfolios and liquidity. While selling can sometimes raise questions, a pre-planned sale mitigates concerns about opportunistic timing and is generally viewed as a routine event in executive compensation.

Related Party Transactions

• The Chief Commercial Officer exercised stock options and sold shares of the company's common stock.

Stakeholder Impact

• Shareholders: May observe an insider selling shares, but the pre-planned nature and option exercise context provide clarity, suggesting it is a routine compensation-related event rather than a signal of declining confidence.

Key Dates

Recommendation

This Form 4 filing details a routine, pre-planned insider transaction where the Chief Commercial Officer exercised stock options and sold an equivalent number of shares. This is a common practice for executives to realize value from their compensation and manage personal liquidity. It does not indicate a change in the company's fundamental outlook or performance, nor does it suggest a lack of confidence in the company's future, especially given the 10b5-1 plan. Therefore, it provides no new information to warrant a change in investment stance.

Keywords

Pulse Biosciences, PLSE, Insider Trading, Form 4, Stock Options, Rule 10b5-1, Chief Commercial Officer, Equity Transaction